LONDON, July 7, 2026, 20:02 BST
- IXICO finished the day at 9.10p, jumping 12.87% as the company raised its FY 2026 revenue outlook, now guiding at least £8.0 million.
- The new target is £0.5 million higher than before. The rally lifted equity value by around £2.1 million, using share count and price.
- H1 revenue came in at £3.9 million. That means the company’s new floor points to at least £4.1 million for the second half.
IXICO Plc (LON:IXI) jumped on Tuesday as the neuroscience imaging company lifted its revenue guidance for the year. Traders sent the stock sharply higher, putting a rich premium on the company’s improved sales outlook. The market is now valuing the upgrade at around four times the projected sales boost for this year.
IXICO shares closed at 9.10p, up 12.87% at 16:35 BST, after the company said full-year revenue will be at least £8.0 million, topping market forecasts and up about 22% from FY 2025. The update hit after the London stock market’s cash session ended at 1630.
The company had forecast £7.5 million before, or 15% growth. The increase is just £0.5 million, not much in cash terms. But the shares moved more. Hargreaves Lansdown listed a market value of £19.93 million, with 218.97 million shares in issue. The price moved up from 8.13p at Monday’s close, adding about £2.1 million in equity.
| Measure | Latest figure | Investor read |
|---|---|---|
| FY 2025 revenue | £6.53 mln | This is the base year |
| Old FY 2026 forecast | £7.5 mln | Expected growth was 15% |
| New FY 2026 floor | £8.0 mln | Now looking at around 22% growth |
| Guidance increase | £0.5 mln | That’s 6.7% above the earlier estimate |
| Market cap after rally | £19.93 mln | Now trades at about 2.5x the new revenue floor |
For investors, that’s what matters. IXICO is still working to show that a larger order book turns into more revenue and better margins. In the first half, revenue hit £3.9 million and gross margin increased to 53%. The order book came in at £18.1 million, up 38% on the year.
The new £8.0 million floor means second-half revenue should hit at least £4.1 million. That’s just 5% higher than the first half, but it’s a key mark for IXICO, which has been running at a loss and where contract timing can swing earnings for smaller firms.
| Revenue bridge | Amount |
|---|---|
| Revenue for H1 2026 | £3.9 mln |
| Updated FY 2026 revenue floor | £8.0 mln |
| Minimum revenue for H2 2026 | £4.1 mln |
| EBITDA loss in H1 2026 | £0.5 mln |
| Order book at H1 2026 | £18.1 mln |
Chief Executive Bram Goorden said the better numbers came from “contract wins, contract extensions, and revenue diversification”. Back in May, he cited the bigger order book as providing “good visibility of future revenues”. Investegate
IXICO raised its guidance after stronger trading from more clients and some contract renewals. AJ Bell’s Alliance News reported on the new £8.0 million revenue floor, swapping out the old £7.5 million estimate.
Shares in IXICO jumped 12.87%, topping the Pharmaceuticals & Biotechnology index, which rose 1.64% to 26,818.60, according to Sharecast data. The FTSE AIM All-Share stood at 769.18.
IXICO ended March with £1.7 million in cash and then raised £10 million after the quarter finished, netting £9.4 million after costs. The extra cash gives management the firepower to pursue IxIco’s TechBio plan, but expectations are higher now.
